Screening methods to identify compounds that modulate type I phosphodiesterase (PDE) activity
View Patent ↗The present invention relates to novel methods of signal transduction in cells. In particular, the invention relates to signal transduction via a class of enzymes known as phosphodiesterase enzymes or PDEs. The invention also relates to a class of signaling molecules known as G-coupled protein receptors (GCPRs) and G-proteins. The invention provides novel methods to screen for and identify G-proteins and other compounds which modulate signaling by these two classes of proteins. In particular, the relates to novel assays which identify compounds that modulate (e.g., enhance or inhibit) binding between a PDE polypeptide and an effector activation domain of a G-protein.
1. A method for identifying a compound that modulates activity of a Type I phosphodiesterase (PDE), which method comprises:
(a) contacting an effector activation polypeptide to a Type I PDE polypeptide under conditions that permit binding of the effector activation polypeptide to the PDE polypeptide, the effector activation polypeptide comprising an effector activation region of a G-protein; and
(b) detecting binding of the effector activation polypeptide to the PDE polypeptide in the presence and in the absence of a test compound,
wherein the test compound is identified as a compound that modulates activity of a Type I PDE if binding of the effector activation polypeptide to the PDE polypeptide is modulated in the presence of the test compound.
2. The method of claim 1 wherein the test compound is identified as a compound that inhibits activity of a Type I PDE if binding of the effector activation polypeptide to the PDE polypeptide decreases in the presence of the test compound.
3. The method of claim 1 wherein the test compound is identified as a compound that enhances activity of a Type I PDE if binding of the effector activation polypeptide to the PDE polypeptide increases in the presence of the test compound.
4. A method for identifying a compound that modulates activity of a Type I phosphodiesterase (PDE), which method comprises:
(a) contacting an effector activation polypeptide to a Type I PDE polypeptide, the effector activation polypeptide comprising an effector activation region of a G-protein; and
(b) detecting PDE activity in the presence and in the absence of a test compound,
wherein the test compound is identified as a compound that modulates activity of a Type I PDE if PDE activity is modulated in the presence of the test compound.
5. The method of claim 4 wherein the test compound is identified as a compound that inhibits activity of a Type I PDE if PDE activity decreases in the presence of the test compound.
6. The method of claim 4 wherein the test compound is identified as a compound that enhances activity of a Type I PDE if PDE activity increases in the presence of the test compound.
7. The method of claim 4 wherein PDE activity is detected according to a method which comprises detecting hydrolysis of a cyclic nucleotide triphosphate (cNMP).
8. The method of claim 7 wherein the cNMP is selected from the group consisting of cAMP and cGMP.
9. The method of claim 1 or 4 wherein the G-protein is a G-protein expressed in a taste receptor cell.
10. The method of claim 9 wherein the G-protein is transducin.
11. The method of claim 10 wherein the effector activation polypeptide comprises the sequence of amino acid residues 293–314 of the transducin alpha-subunit as set forth in FIG. 6 (SEQ ID NO:1).
12. The method of claim 1 or 4 wherein the PDE polypeptide is selected from the group consisting of PDE IA7, PDE IA1, and PDE IC.
13. The method of claim 12 wherein the PDE polypeptide is PDE IA7.
14. The method of claim 12 wherein the PDE polypeptide is PDE IA1.
15. The method of claim 12 wherein the PDE polypeptide is PDE IC.